LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.Cell Rep Med已检查 6 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:ROC 图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 1 张未列出。 | PMID 40480221PMC12208316 | 2025-Jun-17 | 0.70 | The study is an eligible Phase III randomized oncology trial with a drug intervention. However, it does not report a time-to-event efficacy endpoint (such as OS, PFS, etc.) or Kaplan-Meier/HR results; its primary endpoint is pathological response (pCR), which is not a time-to-event outcome. Therefore, it does not meet the core requirement for this cohort. | 无 KM 图 |
| VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults.Aesthet Surg J已检查 8 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 3 张未列出。 | PMID 40246546PMC12168443 | 2025-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of Condoliase on Health-related Quality of Life in Participants With Radicular Leg Pain Associated With Lumbar Disk Herniation: Results From a United States Phase 3 Clinical Trial.Spine (Phila Pa 1976)已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 forest plot。 | PMID 40066868PMC12101895 | 2025-Jun-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40473449无 PMCID | 2025-Jun-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm.Eur J Pediatr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40515786无 PMCID | 2025-Jun-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40517007无 PMCID | 2025-Jun-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.Inflamm Bowel Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图。 | PMID 39326009PMC12166301 | 2025-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.Clin Cancer Res | PMID 40162917PMC12163600 | 2025-Jun-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study.Arthritis Res Ther已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 forest plot;Fig. 2:AI 判定为 forest plot;Fig. 3:AI 判定为 forest plot。 | PMID 40514717PMC12164154 | 2025-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.Blood | PMID 40090011PMC12824683 | 2025-Jun-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40387033无 PMCID | 2025-Jun-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nerandomilast in Patients with Progressive Pulmonary Fibrosis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40388329无 PMCID | 2025-Jun-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40421736无 PMCID | 2025-Jun-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.Circulation | PMID 40156843PMC12144549 | 2025-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.J Clin OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40249893无 PMCID | 2025-Jun-10 | 0.80 | The study is an eligible oncology RCT, but it reports only toxicity outcomes, not the required survival, progression, or other time-to-event efficacy endpoints. | 无 KM 图 |
| Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial.JAMA已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图;Figure 2:ROC 图;Figure 3:AI 判定为 other。 | PMID 40332892PMC12060023 | 2025-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Sodium Oxybate in Adults With Idiopathic Hypersomnia: A Randomized Controlled Trial.NeurologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40359459无 PMCID | 2025-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Inter-cluster contamination: a semivariance analysis of community effect ranges of malaria vector control interventions in a four-armed malaria trial in Muleba, Tanzania.Malar J入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40490768PMC12150443 | 2025-Jun-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Res Ther | PMID 40483523PMC12144695 | 2025-Jun-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study).Jpn J Clin Oncol已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram。 | PMID 39997358PMC12138771 | 2025-Jun-05 | 0.70 | The record describes a randomized Phase III trial for follicular lymphoma with drug interventions (obinutuzumab, bendamustine), but the abstract is a protocol/study description without reporting any efficacy results, including time-to-event endpoints (OS, PFS, etc.) or Kaplan-Meier/HR data. It lacks the required primary or secondary time-to-event efficacy endpoint report. | 无 KM 图 |
| The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.Blood | PMID 40009494PMC12824681 | 2025-Jun-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113.Jpn J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图。 | PMID 40052520PMC12138772 | 2025-Jun-05 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40305708无 PMCID | 2025-Jun-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::森林图/亚组分析图。 | PMID 40466065PMC12269788 | 2025-Jun-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).J Crohns Colitis | PMID 40243842PMC12134888 | 2025-Jun-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial.Oncologist | PMID 40504550PMC12160816 | 2025-Jun-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis.J Bone Miner Res已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 39861972PMC12131232 | 2025-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.Eur J Cancer | PMID 40286474PMC12118534 | 2025-Jun-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40306120无 PMCID | 2025-Jun-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): A phase III crossover trial.Eur J CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40311506无 PMCID | 2025-Jun-03 | 0.95 | The trial is a randomized Phase III oncology study with a drug intervention and presents original primary results, but its primary efficacy endpoint is complete response rate (a proportion), not a time-to-event outcome such as OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR analyses are reported. | 无 KM 图 |
| Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。 | PMID 40323617PMC12053799 | 2025-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.RMD Open入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40461265PMC12142151 | 2025-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.J Infect Dis已检查 1 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 flow diagram。 | PMID 39478672PMC12128069 | 2025-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.J Infect Dis入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40119775PMC12128075 | 2025-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| HPV genotyping agreement between paired cervical cytological sample and biopsy across lesion severity and vaccination.Virol J入排复审未纳入:Record is from a Phase III RCT in oncology but does not report the required survival or time-to-event efficacy outcomes; it focuses on diagnostic test agreement. | PMID 40452051PMC12128532 | 2025-Jun-02 | 0.85 | Record is from a Phase III RCT in oncology but does not report the required survival or time-to-event efficacy outcomes; it focuses on diagnostic test agreement. | 无 KM 图 |
| Comparative study of different treatment modalities for melasma: introducing a novel nanotechnology-based tranexamic acid microemulsion.Arch Dermatol ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40455320无 PMCID | 2025-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of thrombolysis type on the efficacy of aspiration versus stent retriever first line thrombectomy: results from the AcT trial.J Neurointerv Surg入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 39379314无 PMCID | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk.Rheumatology (Oxford)已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 39657237PMC12107077 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies.Rheumatology (Oxford)已检查 4 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:CONSORT/入组流程图。 | PMID 39798135PMC12107048 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39914555无 PMCID | 2025-Jun-01 | 0.85 | The study is a Phase III randomized trial with time-to-event endpoints, but the intervention is radiation therapy (hypofractionated vs. conventional), not a drug-containing intervention. Therefore, it does not meet the eligibility criterion for a drug intervention. | 无 KM 图 |
| Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study.Rheumatology (Oxford)已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 39918968PMC12107041 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial.J Acquir Immune Defic Syndr | PMID 39972543无 PMCID | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.Rheumatology (Oxford) | PMID 40037556PMC12107037 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF.JAMA Cardiol | PMID 40042880PMC11883611 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome.J Clin Sleep Med | PMID 40051199PMC12134589 | 2025-Jun-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.Anesthesiology | PMID 40117446PMC12061372 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.JAMA Cardiol | PMID 40136309PMC11947966 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections.Pediatr Infect Dis J | PMID 40233296PMC12058361 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial.JAMA Intern Med | PMID 40257755PMC12012700 | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.J Drugs Dermatol | PMID 40465504无 PMCID | 2025-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |